The School of Pharmacy announces the appointment to an Honorary Chair in Industrial Pharmacy of Professor Harry Ferres BSc MSc PhD
Prof. Harry Ferres, born in Belfast, is a Queen's graduate in Chemistry who has had a distinguished and outstanding career in the international pharmaceutical industry. Starting in the UK company Beecham, working in the the area of new drug discovery, Dr. Ferres moved progressively to SmithKline Beecham (SKB) and then to GlaxoSmithKline (GSK). His career in the science-based pharmaceutical industry spanned some 35 years.
In the first eighteen years Prof. Ferres led multidisciplinary teams working on antibiotics and cardiovascular agents. His work led to the discovery and launch of the antibiotic Talpen and the thrombolytic agent Eminase, for which he was worldwide scientific advisor. He then moved on to head major areas within preclinical development, including Scientific Support Services within SKB and subsequently, for 10 years, was worldwide head of Pharmaceutical Development for SKB.
Following the merger with Glaxo, Prof. Ferres took on this role with GSK as a Senior Vice-President of the company. This was a strongly pharmacy-orientated activity involving dosage form development. In GSK, Prof. Ferres headed a team of 1500 scientists based in nine sites in five countries. His teams were responsible for the development of several new pharmaceutical products and patented novel dosage form concepts.
In July 2003, Prof. Ferres retired from the pharmaceutical industry. In his new role in the School of Pharmacy, he will contribute to curriculum design and teaching in industrial pharmacy within the MPharm course. Prof. Ferres also chairs the Industrial Advisory Board of the interdisciplinary Medical Polymers Research Institute within Queen's.